Home › Trials › NCT06547398
Clinical trial Recruiting at 1 site Interventional Ages 18 and up Men only

Adaptive radiation for prostate cancer

Official title: Prostate Adaptive Radiation Therapy

Run by Royal North Shore Hospital · NCT06547398 · Data updated 2026-11-12

This study tests whether daily adaptive radiotherapy led by radiation therapists, with the option to use smaller treatment margins, can reduce side effects for men having prostate radiotherapy.

Quick facts

Study typeInterventional
Ages18 Years and up
SexMen only
Enrollment130 (estimated)
SponsorRoyal North Shore Hospital
Academic / other
Drugs / interventionsradiation
Locations1 site (St Leonards, New South Wales)
StatusRecruiting
StartedOctober 1, 2025
Main results expectedOctober 31, 2029
Study endsOctober 31, 2031
Registry record updatedFebruary 5, 2026
Trial IDNCT06547398 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Men over 18 with biopsy-proven prostate cancer scheduled for definitive prostate radiotherapy, ECOG 0–2, able to consent, and without a hip prosthesis or excessive body separation are the intended participants.

Probably not a fit

Patients needing pelvic nodal irradiation, those with a hip prosthesis, or those with prostate-to-skin separation greater than 24 cm are unlikely to be eligible or to benefit from the margin-reduction approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a two-phase, randomized program at Royal North Shore Hospital where phase 1 tests the safety and feasibility of a radiation therapist–led adaptive workflow and phase 2 tests margin-reduced adaptive treatments to lower toxicity. Treatments use image-guided, daily adaptive radiotherapy to account for anatomical changes and may reduce clinical and planning target volume margins compared with standard practice. Eligible participants are adults with biopsy-proven prostate cancer receiving definitive prostate-only radiotherapy, while patients with hip prostheses or excessive body separation are excluded. Primary endpoints are feasibility and safety in phase 1 and patient-reported and clinical toxicity outcomes in phase 2.

Why it matters

Potential benefit: If successful, this approach could lower radiation side effects and improve quality of life by safely reducing treatment margins.

How similar studies have gone: Earlier adaptive radiotherapy studies have shown promising reductions in acute toxicity, but RT-led daily adaptive workflows and randomized margin-reduction approaches are relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. \- Age \> 18
2. Biopsy proven prostate malignancy
3. Definitive treatment is radiotherapy to the prostate alone
4. ECOG performance status 0-2
5. Ability to understand and the willingness to sign an informed consent

Exclusion Criteria:

1. Hip prosthesis
2. Patient separation from prostate centre to skin edge \> 24cm, measured on diagnostic scan-

Where it's running

  • Northern Sydney Cancer Centre, Royal North Shore Hospital
    St Leonards, New South Wales, Australia     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostatic Neoplasms 37Royal North Shore Hospital 9
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.